Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3477)
All Articles published online
|
Publishing Process of This Article
|
Oct 15, 2023 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Navadurong H, Prasoppokakorn T, Siriwong N, Phathong C, Teeyapun N, Tanasanvimon S, Thanapirom K, Komolmit P, Tangkijvanich P, Treeprasertsuk S, Chaiteerakij R. Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy. World J Gastrointest Oncol 2023; 15(10): 1771-1783 [PMID: 37969413 DOI: 10.4251/wjgo.v15.i10.1771] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i10/1771.htm |
| Number | Citing Articles |
| 1 |
Tao Sun, Xiangkun Wang, Guangcan Zhu, Jinfu Zhang, Juan Huang, Renfeng Li, Xinguang Qiu. The EZ-ALBI and PALBI scores contribute to the clinical application of ALBI in predicting postoperative recurrence of HCC. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-93716-9
|
| 2 |
Zhengzheng Ji, Jiasong Li, Shasha Zhang, Yuanyuan Jia, Jing Zhang, Zhanjun Guo. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1480520
|
| 3 |
Supachaya Sriphoosanaphan, Witthawat Pantumongkol, Wantanee Kulpeng, Chanchai Charonpongsuntorn, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Abhasnee Sobhonslidsuk, Pisit Tangkijvanich, Jincheng Wang. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand. PLOS ONE 2024; 19(3): e0300327 doi: 10.1371/journal.pone.0300327
|